Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2021 Jan 20

PMID 33469357

Citations 3

Authors

Jesse Lopes da Silva

Fabiana Resende Rodrigues

Guilherme Gomes de Mesquita

Priscila Valverde Fernandes

Luiz Claudio Santos Thuler

Andreia Cristina de Melo

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate the influence of immunohistochemical (IHC) biomarkers in the response to neoadjuvant chemotherapy (NACT) and survival outcomes in the subset of locally advanced triple-negative breast cancer (TNBC).

Materials And Methods: The epidermal growth factor receptor (EGFR), androgen receptor (AR), cytokeratins (CK5/6, CK14 and CK17), Ki67 and p53 immunohistochemistry were evaluated on 171 cases of TNBC submitted to NACT and subsequently to surgery. Intensity and percentage of the expression of these biomarkers were combined to formulate a specific score, that was correlated with prognostic features and assessed for survival outcomes.

Results: Most patients had advanced clinical-stage tumors (stage III: 83.6%; cT3/T4: 85.9%; cN1-3: 71.3%). The predominant histological subtype was high-grade (67.3%) and invasive ductal carcinoma (93.6%). The residual cancer burden (RCB) 0-1 corresponded to 28.7% of cases and low-risk lymph node ratio (LNR) represented 77.2%. High Ki67 expression only showed a significant correlation with grade 3 tumors (p = 0.0157). CK5/6 was observed in 16% (27/169), CK14 was positive in 10.1% (17/169), CK17 in 91.1% (153/168), p53 in 52.6% (70/133), EGFR in 92.9% (157/169 cases), AR in 13% (22/169) and Ki67 index was scored ≥40% in 57.9% (95/165). No IHC biomarker significantly impacted response or survival. Regarding the analysis of the outcomes of event-free survival (EFS) and overall survival (OS), clinical stage (p = 0.014 and p = 0.042, respectively), RCB (p < 0.0001 and p <0.0001, respectively) and LNR (p <0.0001 and p <0.0001, respectively) showed significant association.

Conclusion: No IHC biomarker evaluated showed a significant association with a response or survival outcomes in TNBC patients. Clinical stage, LNR and RCB stood out for strongly influencing survival.

Citing Articles

Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.

Blaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A Cancers (Basel). 2025; 17(2).

PMID: 39858010 PMC: 11764116. DOI: 10.3390/cancers17020228.

Crocin inhibit the metastasis of MDA-MB-231 cell line by suppressing epithelial to mesenchymal transition through WNT/β-catenin signalling pathway.

Ghorbanzadeh V, Hassan Aljaf K, Wasman H, Dariushnejad H Ann Med Surg (Lond). 2024; 86(3):1401-1407.

PMID: 38463069 PMC: 10923327. DOI: 10.1097/MS9.0000000000001691.

Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.

Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P Viruses. 2023; 15(12).

PMID: 38140561 PMC: 10748233. DOI: 10.3390/v15122320.

The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis.

Liu J, Li Y, Zhang W, Yang C, Yang C, Chen L Front Surg. 2022; 9:971030.

PMID: 36386510 PMC: 9644128. DOI: 10.3389/fsurg.2022.971030.

References

da Silva J, Nunes N, Izetti P, Gomes de Mesquita G, de Melo A . Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020; 145:102855. DOI: 10.1016/j.critrevonc.2019.102855. View

Wang X, Liu Q, Sun J, Zuo W, Hu D, Ma S . Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res. 2015; 14(2):4282-90. DOI: 10.4238/2015.April.28.10. View

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N . Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009; 20(12):1913-27. DOI: 10.1093/annonc/mdp492. View

Peng Y, Butt Y, Chen B, Zhang X, Tang P . Update on Immunohistochemical Analysis in Breast Lesions. Arch Pathol Lab Med. 2017; 141(8):1033-1051. DOI: 10.5858/arpa.2016-0482-RA. View

Trivers K, Lund M, Porter P, Liff J, Flagg E, Coates R . The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009; 20(7):1071-82. PMC: 4852686. DOI: 10.1007/s10552-009-9331-1. View

Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J . Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer. 2012; 21(1):66-74. DOI: 10.1007/s12282-012-0354-1. View

Petitjean A, Achatz M, Borresen-Dale A, Hainaut P, Olivier M . TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26(15):2157-65. DOI: 10.1038/sj.onc.1210302. View

Chiu A, Mitra M, Boymoushakian L, Coller H . Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Sci Rep. 2018; 8(1):11807. PMC: 6081411. DOI: 10.1038/s41598-018-29992-5. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Lara J, Thor A, Dressler L, Broadwater G, Bleiweiss I, Edgerton S . p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011; 17(15):5170-8. PMC: 3149770. DOI: 10.1158/1078-0432.CCR-11-0484. View

11.

He J, Peng R, Yuan Z, Wang S, Peng J, Lin G . Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2011; 29(2):406-10. DOI: 10.1007/s12032-011-9832-0. View

12.

Hilborn E, Gacic J, Fornander T, Nordenskjold B, Stal O, Jansson A . Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. Br J Cancer. 2016; 114(3):248-55. PMC: 4742586. DOI: 10.1038/bjc.2015.464. View

13.

Matsubara N, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S . Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 2014; 147(1):95-102. DOI: 10.1007/s10549-014-3084-6. View

14.

Irvin Jr W, Carey L . What is triple-negative breast cancer?. Eur J Cancer. 2008; 44(18):2799-805. DOI: 10.1016/j.ejca.2008.09.034. View

15.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

16.

Niemeier L, Dabbs D, Beriwal S, Striebel J, Bhargava R . Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2009; 23(2):205-12. DOI: 10.1038/modpathol.2009.159. View

17.

Thor A, Moore DH I, Edgerton S, Kawasaki E, Reihsaus E, Lynch H . Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992; 84(11):845-55. DOI: 10.1093/jnci/84.11.845. View

18.

Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W . Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. Front Oncol. 2019; 9:1068. PMC: 6811517. DOI: 10.3389/fonc.2019.01068. View

19.

Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

20.

Coates A, Millar E, OToole S, Molloy T, Viale G, Goldhirsch A . Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res. 2012; 14(6):R143. PMC: 4053129. DOI: 10.1186/bcr3348. View